Product Description
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | Cyprus | Egypt | Hong Kong | India | Ireland | Italy | Jordan | Korea | Lebanon | Malaysia | Mexico | Pakistan | Peru | South Africa | Taiwan | United Arab Emirates | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|